Company Overview and News

7
Kraft Heinz Is Struggling

2018-09-18 seekingalpha
The entire packaged goods sector has been struggling of late. Kraft Heinz has been no exception to the rule.
BRK.A UL CPB KHC

 
CPB / Campbell Soup Co. PRELIMINARY PROXY STATEMENT IN CONNECTION WITH CONTESTED SOLICITATIONS

2018-09-14 sec.gov
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )
CPB

15
Grossman Is Engineering a Real Weight Watchers Stock Turnaround

2018-09-12 investorplace
Weight Watchers (NYSE:WTW) CEO Mindy Grossman is one of the most brilliant executives of our time and there are lots of high expectations about what she can do for Weight Watchers stock.
GS NKE RL CPB WTW CLX HSY

 
CPB / Campbell Soup Co. / Third Point LLC - SCHEDULE 13D/A (AMENDMENT NO. 1) (Activist Investment)

2018-09-07 sec.gov
Schedule 13D/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wash
CPB

3
CPB / Campbell Soup Co. / Third Point LLC - SCHEDULE 13D/A (AMENDMENT NO. 1) (Activist Investment)

2018-09-07 sec.gov - 3
Schedule 13D/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wash
CPB

 
Dan Loeb and Third Point Launch Proxy Fight for Campbell Soup Board

2018-09-07 247wallst
Campbell Soup Co. (NYSE: CPB) has been at the center of attention over the summer, first as its CEO stepped down and then for pursuing a sale of the company. Now activist investor Dan Loeb and his firm Third Point are looking to further take control of Campbell and influence a sale, this time through the board of directors.
CPB

4
J.M. Smucker: Time To Buy?

2018-09-05 seekingalpha
I like the very low expectations in combination with a reasonable positioning and still-manageable leverage ratio.
SJM CPB

306
Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha - 8
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
HIBB JWN DKS AVGO APRN PCB SODA AMC TMUS PDYPF AKCA JONE COUP SOLO REV MESA CZR LJPC VZ HEAR FCAU BRC MGM GCO FB ULTA IGT TM IRBT VCNX CTXR LB GMVHF MTCH DBX KS JNEEP AAPL USAK TSG ZAGG PRTY KSU DDS MRVL COOL HMC GBX TSCO DSKE MU DG WRK BYD LOW LRCX TXN CTRP TWX HA SKYW GNC RCL RH UAL PFCF AMZN TWTR CATO BKS VLKAY OSTK AAL BKE BBY GWRE MDLZ GME ON NSC NAV GOOGL QCOM HD XLNX CHDN CPB WDAY FND JBLU QSII WIMHY ALK ADBE MDXG GM GOGO CROX DAL CWH WIMHF F TECH PANW COST M SAVE WMH W S PEP URBN

6
Top Analyst Upgrades and Downgrades: Ambarella, Apple, Campbell Soup, Ciena, Dollar Tree, Electronic Arts, Lululemon, Signet Jewelers, Ulta and More

2018-08-31 247wallst
Stocks were indicated lower on Friday after taking a breather on Thursday. The market indexes may have recently hit all-time highs after a strong earnings season, but investors have seen less upside from the “buy the sell-offs” mentality that worked several years. Those same investors also are trying to decide how they want their investments positioned for the rest of 2018.
DLTR EA SIG DB CPB AAPL DG TRI AMBA CIEN SIG

 
Campbell Soup Stock Feeling the Pressure of Disappointing Sales

2018-08-30 investorplace
Campbell Soup stock was down on Thursday following the release of its earnings report for its fiscal fourth quarter of 2018.
CPB

 
Campbell Soup’s Plan to Save Itself

2018-08-30 247wallst
In May, Campbell Soup Inc. (NYSE: CPB) CEO Denise Morrison unexpectedly resigned and the company announced that it had begun a full-scale operational review of its businesses. Interim CEO Keith McLoughlin announced the first results of that review Thursday morning when the company also reported fourth-quarter and fiscal year 2018 results.
CPB

1
CPB / Campbell Soup Co. 8-K (Current Report)

2018-08-30 sec.gov - 1
Document UNITED STATES
CPB

 
Campbell Soup Under Pressure

2018-08-30 seekingalpha
Campbell Soup (NYSE:CPB), best known for its eponymous line of canned soups, has stumbled in recent years. The firm's struggles culminated in the unexpected departure of CEO Denise Morrison in late May, following the report of weaker than expected Q3 earnings and lowered FY 2018 guidance on May 18th.
CPB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CPB / Campbell Soup Co. on message board site Silicon Investor.

Speculating in Takeover Targets Speculating in Takeover Targets Speculating in Takeover Targets CPB Campbell soup CPB Campbell soup CPB Campbell soup
CUSIP: 134429109